Certain proteins found in the human brain have long been known to be critical to controlling how brain cells communicate with each other. So-called GABAA receptors are proteins that control the flow ...

A paradigm-shifting study from the Centre for Addiction and Mental Health (CAMH) shows an experimental drug, GL-II-73, has ...

γ-aminobutyric acid (GABA), whether it be lower levels of GABA or the receptor it binds to. But a study published last week (October 3) in Science Translational Medicine, which zeroed in on GABA ...

As results indicated that the spinal antinociceptive effect of diazepam is mediated predominately by GABA A receptor isoforms containing the α2 and α3 subunits, the authors next tested whether ...

Scientists have discovered a potential new drug that could help people with Alzheimer’s disease by improving memory and ...

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on delivering therapeutics through effective oral delivery, announced today that it has received revised regulatory guidance for LPCN ...

Algiax Pharmaceuticals, a clinical-stage biotech company focused on developing innovative treatments for chronic neuropathic pain, today announced compelling topline data from its Phase 2a clinical ...

When GABA receptors are stimulated, they reduce neuron firing, leading to sluggish movement. 3 This wobbly effect isn’t limited to humans; Rossi found that rodents exhibit similar behavior. He tested ...

Relmada purchases Sepranolone, a Phase 2b ready asset, for the treatment of Tourette syndrome (TS) and other compulsion-related conditions from ...

Detailed price information for Revive Therapeutics Ltd (RVVTF) from The Globe and Mail including charting and trades.

A paradigm-shifting study from the Centre for Addiction and Mental Health (CAMH) shows an experimental drug, GL-II-73, has the potential to restore memory and cognitive function in a mouse model of ...

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced receipt of revised ...